Tom Beausejour

Tom Beausejour

Private Equity Investor chez MedEquity Capital LLC

Consumer Services
Finance
Commercial Services

Profil

Tom joined MedEquity Capital in 2016.
His primary responsibilities include sourcing and executing new platform investments, as well as working with portfolio company management teams to plan and execute on their respective growth strategies.
Tom also currently serves as a Director of Riverside Oral Surgery Management.
Prior to MedEquity, Tom worked in both corporate and advisory arenas, most recently at Vertex Pharmaceuticals, a Boston-based biotechnology firm which develops and commercializes novel drug therapies.
At Vertex, Tom managed all financial and valuation exercises used by senior leadership for optimal decisions on mergers and acquisitions, licensing and strategic initiatives.
Prior to Vertex, Tom was a valuation consultant at Duff & Phelps, now Kroll, where he managed client engagements for strategic, financial and tax purposes across a myriad of industries.
Tom has a degree in Finance from Boston College (Magna Cum Laude) and an MBA from the Harvard Business School.
He is also a Chartered Financial Analyst (CFA) and a member of the CFA Institute.
While not working, he enjoys spending time with his wife and young children, golfing and reading.

Postes actifs de Tom Beausejour

SociétésPosteDébut
Private Equity Investor 01/09/2016
Tous les postes actifs de Tom Beausejour

Anciens postes connus de Tom Beausejour

SociétésPosteFin
Private Equity Investor 01/06/2014
Voir l'expérience en détail de Tom Beausejour

Formation de Tom Beausejour

Boston College Graduate Degree
Harvard Business School Masters Business Admin

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Tom Beausejour

Relations

100 +

Relations au 1er degré

4

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées2

Finance

Commercial Services

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Tom Beausejour